EUCTR2006-004451-38-FR进行中（未招募）1 期
A PHASE 2 EFFICACY AND SAFETY STUDY OF SU011248 IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AND BRAIN METASTASES
Pfizer Inc. - 235 East 42nd Street - New York - 100170 个研究点目标入组 60 人开始时间: 2007年12月20日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Histologically or cytologically confirmed NSCLC
- •2. Radiologically proven brain metastases secondary to histologically or cytologically
- •confirmed NSCLC. Prior resection of brain metastases is allowed provided at least 1
- •metastatic brain lesion can be followed by postoperative MRI.
- •3. Previous whole brain radiation therapy =2 weeks prior to study entry.
- •4. None or 1 prior systemic therapy for the treatment of advanced/metastatic NSCLC.
- •5. Patients who received prior systemic therapy for the treatment of NSCLC must have
- •evidence of disease progression.
- •6. Completion of all prior chemotherapy, immunotherapy, and radiotherapy =4 weeks prior to study entry, and resolution of all acute toxic effects of any prior systemic anticancer therapy, radiotherapy, or surgical procedure to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grade =1. Note: WBRT may have occurred =2 weeks prior to study entry.
- •7. For systemic disease, evidence of unidimensionally measurable disease. Measurable brain disease is not required.
- •8. Male or female, 18 years of age or older.
- •9. ECOG performance status 0 or 1.
- •10. Adequate organ function as defined by the following criteria:
- •Serum aspartate aminotransferase (AST; serum glutamate-oxalate transferase
- •[SGOT]) and serum alanine aminotransferase (ALT; serum glutamate-pyruvate
- •transferase) [SGPT] =2.5 x upper limit of normal (ULN)
- •Total serum bilirubin =1.5 mg/dL
- •Prothrombin time (PT) =1.5 x ULN
- •Absolute neutrophil count (ANC) =1500/mL
- •Platelets =100,000/mL
- •Hemoglobin =9.0 g/dL
- •Serum creatinine =1.5 x ULN
- •Sodium =120 mEq/L
- •Left ventricular ejection fraction (LVEF) > 50% as measured by either multigated acquisition (MUGA) scan or echocardiogram (ECHO)
- •11. Signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all pertinent aspects of the trial prior to enrollment.
- •12. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Brainstem lesions, spinal cord compression, carcinomatous meningitis, or
- •leptomenengeal disease
- •2. Brain metastases >4 cm in any linear direction
- •3. Candidate for definitive therapy for brain metastases (e.g. Gamma Knife, surgery).
- •4. Evidence of tonsillar or tentorial herniation
- •5. Intracranial or intratumoral hemorrhage (except those with punctuate asymptomatic intratumoral bleeds).
- •6. Uncontrolled seizure activity
- •7. Treatment with potent CYP3A4 enzyme inducers or inhibitors within the past 2 weeks.
- •Note 1: Patients on steroids must be dose reduced to the lowest possible dose if steroids cannot be completely discontinued.
- •Note 2: Steroid dose must be stable (or decreasing) for at least 2 weeks at the time of study entry.
- •Note 3: Patients taking anticonvulsants that affect CYP3A4 enzyme activity (e.g.
- •phenytoin, carbamazepine) must switch to an anticonvulsant that is not a potent enzyme inducer, e.g. Keppra(levetiracetam).
- •8. Ongoing treatment with therapeutic doses of Coumadin.
- •9. Major surgery or radiation therapy <4 weeks of starting the study treatment. Prior
- •palliative radiotherapy to metastatic lesion(s) is permitted, provided there is at least one measurable lesion that has not been irradiated.
- •Note 1: WBRT must have occurred = 2 weeks prior to study entry.
- •Note 2: Resection of brain metastases is allowed provided at least 1 metastatic lesion is available for follow-up.
- •10. NCI CTCAE Grade 3 hemorrhage <4 weeks of starting study treatment.
- •11. Evidence of hemoptysis <4 weeks of starting study treatment. Patients with blood-tinged or blood-streaked sputum will be permitted on study if the hemoptysis amounts to <5 mL of blood per episode and <10 mL of blood per 24-hour period in the best estimate of the investigator.
- •12. Uncontrolled hypertension defined as blood pressure >150/100 mm Hg that cannot be controlled with standard antihypertensive agents.
- •13. Diagnosis of any second malignancy within the last 3 years, except basal cell carcinoma, squamous cell skin cancer, or in situ carcinoma that has been adequately treated with no evidence of recurrent disease for 12 months.
- •14. Any of the following within the 12 months prior to study drug administration: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, congestive heart failure, cerebrovascular accident including transient ischemic attack, or pulmonary embolism.
- •15. Ongoing cardiac dysrhythmias of NCI CTCAE grade =2, atrial fibrillation of any grade, or prolongation of the QTc interval to >450 msec for males or >470 msec for females.
- •16. Known human immunodeficiency virus (HIV) infection.
- •17. Current treatment on another therapeutic clinical trial.
- •18. Pregnancy or breastfeeding. Female patients must be surgically sterile or be
- •postmenopausal, or must agree to use effective contraception during the period of
- •therapy. All female patients with reproductive potential must have a negative pregnancy test (serum or urine) prior to study treatment.
- •19. Other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator would make the patient inappropriate for entry into this study.
- •20. Receipt of any investigational agent within 4 weeks prior to study entry.
研究者
相似试验
进行中（未招募）
不适用
A PHASE 2 EFFICACY AND SAFETY STUDY OF SU011248 IN COMBINATION WITH TRASTUZUMAB AS TREATMENT FOR METASTATIC DISEASE IN PATIENTS WITH BREAST CANCERlocally recurrent or metastatic BCMedDRA version: 7.1Level: LLYClassification code 10055113EUCTR2005-003773-25-BEPFIZER s.a.128
进行中（未招募）
不适用
A PHASE 2 EFFICACY AND SAFETY STUDY OF SU011248 IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AND BRAIN METASTASES - NDon-Small Cell Lung Cancer NSCLC patients with brain metastasesMedDRA version: 9.1Level: LLTClassification code 10059515Term: Non-small cell lung cancer metastaticEUCTR2006-004451-38-ITPFIZER60
进行中（未招募）
1 期
A PHASE 2 EFFICACY AND SAFETY STUDY OF SU011248 IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCERHistologically proven NSCLC (Stage IV or recurrent disease or locally advanced [Stage IIIB]) that is not amenable to surgery, radiation, or combined modality therapy with curative intentEUCTR2004-001467-22-ESPfizer S.A.60
进行中（未招募）
不适用
A PHASE 2 EFFICACY AND SAFETY STUDY OF SU011248 IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCEREUCTR2004-001467-22-ITPFIZER60
进行中（未招募）
不适用
A PHASE I/II EFFICACY AND SAFETY STUDY OF SU011248 IN PATIENTS WITH RECURRENT OR METASTATIC NON-NASOPHARYNGEAL HEAD AND NECK CANCERRecurrent or metastatic non-nasopharyngeal head and neck cancerEUCTR2005-004939-22-GRHellenic Cooperative Oncology Group (HeCOG)